Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2025-12-25 @ 1:47 PM
Study NCT ID:
NCT03534492
Status:
COMPLETED
Last Update Posted:
2020-04-06
First Post:
2018-05-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)
Sponsor:
Spanish Oncology Genito-Urinary Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-11-16
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-03-16
Completion Date Type:
ACTUAL
First Submit Date:
2018-05-11
First Submit QC Date:
None
Study First Post Date:
2018-05-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-04-03
Last Update Post Date:
2020-04-06
Last Update Post Date Type:
ACTUAL